Quantum-Si Widens Proteus Roadshow to Nine European and US Stops

Quantum-Si Incorporated (NASDAQ: QSI) announced an expansion of its Proteus roadshow on Wednesday, adding stops in Leiden, Paris, London, Denver, New York, Barcelona, Rome, Munich and Berlin through November, with shares roughly flat at $0.76 as of 15:22 GMT.

Quantum-Si Incorporated (NASDAQ: QSI) spent Wednesday going nowhere in particular. The proteomics company said it is widening the roadshow built around Proteus, its single-molecule protein sequencing platform, adding stops across the United States and Europe through the autumn. The stock traded at $0.76, down 0.64% on the day against a prior close of $0.76, inside a session band of $0.75 to $0.77 as of 15:22 GMT.

That flatness came on a soft tape. The S&P 500 proxy SPY was at $761.79, off 0.54%, with the Nasdaq 100 proxy QQQ at $715.55, down 0.39%, and the Dow tracker DIA at $523.60, down 0.84%. A sub-dollar life-sciences instrument holding its ground while the large-cap indices slip is not a rally, but it is not a rejection of the news either.

What Quantum-Si actually announced

The company described an expansion of a program it last updated in June. The near-term schedule runs Leiden on September 11, Paris on September 14 and London on September 15, then crosses the Atlantic to the University of Colorado Anschutz Medical Campus on September 22 and New York on September 24.

The fourth quarter picks up in southern Europe: Barcelona on October 14 and Rome on October 16, both run with a local channel partner, followed by Munich on November 2 and Berlin on November 4. Alongside the roadshow, Quantum-Si said five further seminars will be hosted with academic, clinical research and biopharma partners at selected sites in the US and Europe.

Counting the named cities gives nine roadshow stops from September through early November, plus the five partner seminars — a fourteen-event calendar over roughly eight weeks, as reported by Baystreet.

Why a roadshow is the sales channel for this technology

Single-molecule protein sequencing reads individual protein molecules one at a time, rather than inferring protein identity in bulk from mass spectrometry signals. Proteomics — the study of the full set of proteins expressed by a cell or organism — has lagged genomics commercially in part because the instrumentation is less standardised and the workflows less familiar to the people who would buy them.

That is the problem a roadshow is designed to solve. Quantum-Si framed the events explicitly as market education. When a platform asks a lab to change how it does an experiment, the buying decision is made by a principal investigator or core facility director who wants to see the instrument run and talk to someone who has used it. Conference booths and webinars do not close that gap; a demonstration on a university campus can.

The choice of venues reinforces the point. The University of Colorado Anschutz Medical Campus is an academic medical centre, not a trade fair. Leiden is a Dutch life-sciences hub. The Barcelona and Rome dates run through a local channel partner, which is how instrument makers typically reach markets where they lack direct sales headcount — the partner brings the customer relationships and handles installation and service.

What the share price is telling investors

The market reaction is the honest part of the story. A roadshow is a commercial input, not a commercial result. It does not book revenue, does not confirm placements and does not disclose a pipeline. Investors in early-stage instrument companies have learned to price these announcements as intention rather than outcome, and a move of well under one percentage point is consistent with that reading.

At $0.76, Quantum-Si trades as a small, speculative name where each incremental instrument placement matters disproportionately to the revenue line. That cuts both ways: the operating leverage on a successful commercial push is large, and so is the sensitivity to a slow one. Sub-dollar quotations also carry their own housekeeping issues on major US exchanges, which have minimum bid price requirements — a fact that gives management a reason to convert commercial activity into visible results sooner rather than later.

Metrics that would turn the calendar into evidence

The useful checkpoints are not the events themselves but what follows them. Three things are worth watching over the next two reporting periods.

• Instrument placements and their geography. If the European stops are working, the mix of new placements should tilt toward Europe in the quarters after Leiden, Paris, London, Barcelona, Rome, Munich and Berlin.
• Channel partner disclosure. Quantum-Si named a local channel partner for the Italian and Spanish dates without identifying it. Whether that relationship broadens into a formal distribution agreement, and on what economics, will say more about European ambitions than any single seminar.
• Consumables pull-through. Sequencing businesses live on recurring reagent and consumable revenue after the box is sold. A rising installed base that does not generate proportional consumable sales suggests instruments are sitting idle.

The five partner seminars deserve separate attention. Events co-hosted with biopharma organisations are a different signal from academic demonstrations: pharmaceutical customers buy in volume, run validated workflows and sign multi-year supply arrangements. Academic sites build scientific credibility and generate the published papers that persuade the next buyer. A company needs both, but they pay off on different timelines.

The wider proteomics backdrop

Protein analysis has been the sector's persistent promise for years: genomes tell you what a cell might do, proteomes tell you what it is doing. The commercial difficulty has been that competing measurement approaches are entrenched and the incumbent instruments are already paid for. Displacing them requires proving not just that a new method works, but that it answers questions the old method cannot.

That is a slow argument to win, and it is won lab by lab. Quantum-Si's decision to spend the autumn physically in front of researchers in nine cities is a reasonable response to that reality. Whether it converts into orders is a question the next set of financial results will answer, and the flat share price on Wednesday suggests investors intend to wait for them.

Key facts

• Share price: QSI $0.76, -0.64% as of 15:22 GMT, Sept 9, 2026
• Day range: $0.75–$0.77; prior close $0.76
• Roadshow stops named: Leiden, Paris, London, Denver (CU Anschutz), New York, Barcelona, Rome, Munich, Berlin
• Additional events: Five seminars with academic, clinical research and biopharma partners

Frequently asked questions

What did Quantum-Si announce on September 9, 2026?

Quantum-Si announced an expansion of the roadshow supporting its Proteus single-molecule protein sequencing platform. The program has grown since a June update to include stops in Leiden, Paris, London, the University of Colorado Anschutz Medical Campus, New York, Barcelona, Rome, Munich and Berlin, plus five partner-hosted seminars in the US and Europe.

How did QSI shares react?

Barely at all. Quantum-Si traded at $0.76 as of 15:22 GMT on September 9, 2026, down 0.64% from a prior close of $0.76, within a session range of $0.75 to $0.77. That was roughly in line with a soft broader market, where the S&P 500 tracker fell 0.54% and the Nasdaq 100 tracker fell 0.39%.

What is single-molecule protein sequencing?

It is a method of identifying proteins by reading individual protein molecules one at a time, rather than inferring composition from bulk measurements such as mass spectrometry. Proteomics — the study of the complete set of proteins in a cell or organism — has been harder to commercialise than genomics because workflows are less standardised and incumbent instruments are entrenched.

When are the fourth-quarter 2026 roadshow dates?

Quantum-Si listed Barcelona on October 14 and Rome on October 16, both run in collaboration with a local channel partner, followed by Munich on November 2 and Berlin on November 4. Those four stops follow the September schedule in Leiden, Paris, London, Colorado and New York.

Why does a roadshow matter for an instrument company?

Laboratory instruments are sold through demonstration. Principal investigators and core facility directors typically want to see a machine run and speak to existing users before committing budget. Roadshows and on-site seminars are how instrument makers shorten that evaluation cycle, particularly when the technology asks buyers to change an established experimental workflow.

What should investors watch after these events?

The follow-through rather than the calendar: new instrument placements and whether they skew toward Europe, any formalisation of the unnamed local channel partner relationship into a distribution agreement, and consumables revenue per installed instrument. A growing installed base without matching consumable sales would suggest machines are not being used heavily.

Sources

• Quantum-Si Flat on Kicking off Roadshow — Baystreet

Photo: Edward Jenner · Pexels Licence — source